Coherus BioSciences(CHRS) Stock Price Today

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Investors Don't See Light At End Of Coherus BioSciences, Inc.'s (NASDAQ:CHRS) Tunnel And Push Stock Down 27%
Simply Wall StMar 28 07:14 ET
Express News | Coherus To Present Data From Phase 1 Dose Expansion Study Of CHS-114 At 2025 American Association For Cancer Research Annual Meeting
BenzingaMar 25 16:31 ET
Hospital Stocks Are Ready to Rebound, Deutsche Bank Says
BNN BloombergMar 25 13:51 ET
Proposed Medicaid Cuts Would Devastate Local Economies: Report -- Barrons.com
Barron'sMar 25 00:01 ET
Statutory Earnings May Not Be The Best Way To Understand Coherus BioSciences' (NASDAQ:CHRS) True Position
Yahoo FinanceMar 24 06:30 ET
We Believe Coherus BioSciences' (NASDAQ:CHRS) Earnings Are A Poor Guide For Its Profitability
Simply Wall StMar 24 06:26 ET

Comments

Teddy123

Mar 26 14:46

Coherus to Present Data from a Phase 1 Dose Expansion Study of CHS-114, a Cytolytic Antibody Targeting Chemokine Receptor 8 (CCR8), at the 2025 American Association for Cancer Research (AACR) Annual M

$Coherus BioSciences (CHRS.US)$
Breakthrough Cancer Treatment Data: Coherus' CCR8 Antibody Shows Promise in Head & Neck Cancer Trial

2

1

suhaimisarip

Mar 14 16:44

Udenyca sale to Accord

$Coherus BioSciences (CHRS.US)$
Upon the completion of the Udenyca divestiture and pay-off of our significant debt and royalty obligations, we are projecting a cash position of approximately $250 million,” Coherus CEO Denny Lanfear said in the release. “These efforts, combined with organizational streamlining, are expected to provide Coherus with a cash runway exceeding two years, funding the development pipeline through key data catalysts in 2025 and 2026.”
This clinical-s...

2

Ducati999

Mar 11 11:31

Squeeze the Shorties!

$Coherus BioSciences (CHRS.US)$ Embrace this, the convertible bond shorties going to be squeeze soon!

2

suhaimisarip

Mar 11 05:55

2024 net income

$Coherus BioSciences (CHRS.US)$
Net income (loss) for the fourth quarter of 2024 was a net loss of $50.7 million, or $(0.44) per share on a diluted basis, compared to a net loss of $79.7 million, or $(0.71) per share on a diluted basis for the same period in 2023.
Net income for the year ended December 31, 2024 was $28.5 million, or $0.25 per share on a diluted basis, compared to a net loss of $237.9 million, or $(2.53) per share on a diluted basis for year ended December 31, 202...